Many elderly patients with metastatic renal cell carcinoma (RCC) — who are often underrepresented in clinical trials to treat the kidney cancer — are seeing overall survival benefits from treatment with targeted therapies, according to a new study published in JAMA Network Open.
Source: EurekaAlert, https://www.eurekalert.org